Gedeon Richter agrees to acquire Mayne Pharma for A$604M 🤝
Hungarian drugmaker Gedeon Richter has agreed to buy ASX-listed Mayne Pharma for A$604M, or A$6.40 a share, a 99.4% premium to Mayne's last closing price. Richter specialises in women's health, and the deal expands its US women's health business, where Mayne's portfolio includes an estetrol-based contraceptive pill. Completion is expected in March 2027, subject to approvals.
“Innovation has been at the core of making Richter one of the leading players in women's health in Europe and beyond.”
— László Kovács, Deputy CEO, Gedeon Richter
Hone Health raises $228M and expands its women's health offering 💰
US longevity platform Hone Health has raised $228M: a $28M Series A extension led by MarcyPen Capital Partners and $200M of growth financing from General Catalyst's Customer Value Fund. Hone pairs biomarker testing with physician-led treatment, including menopause hormone therapy, and is adding a PMOS (formerly PCOS) care pathway and more postpartum support. It is also using longitudinal patient data to research hormone dosing for women.
Therabody acquires Embr Labs' menopause technology 🌡️
Therabody, the company behind Theragun, has acquired the IP portfolio of MIT-founded Embr Labs, including the thermal technology behind the Embr Wave, a wrist-worn device that cools or warms to ease hot flushes. Nearly 250,000 devices have been sold across two generations, and terms were not disclosed. The deal builds on Therabody's women's health push, including more than $1M committed to research since 2022.
“From developing the original Embr Wave to pioneering AI-driven hot flash prediction, our goal has always been about one thing: delivering real, immediate relief to the people who need it most.”
— Matt Smith, CTO and Co-founder, Embr Labs
On commits $2.3M to help women and girls move 🏃♀️
.Sportswear brand On has launched Her Right To Move, committing $2.3M to grassroots organisations through 2027 to tackle the barriers that stop women and girls being active. Built with the Running Industry Diversity Coalition, it follows research finding fear of harassment (33%) and limited time (32%) among the biggest barriers.
.png)

